Biotech | February 17, 2022
Pebble engages MD Anderson to evaluate multi-cannabinoid formulations in ovarian cancer
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The recommendation has been sent to the DCGI for approval
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
